URNOZ 450 SR Tablet

What is URNOZ 450 SR Tablet?

Each URNOZ 450 SR Tablet contains Ursodeoxycholic Acid (UDCA) 450 mg in sustained‑release form. UDCA reduces cholesterol saturation in bile, helps dissolve cholesterol gallstones, improves bile flow and protects liver cells from toxic bile acids.​

Key Benefits

• Dissolves certain cholesterol gallstones in patients with a functioning gallbladder, offering a non‑surgical option in selected cases.​

• Improves liver function in cholestatic liver disease, including primary biliary cholangitis and fatty liver–related cholestasis, by normalising liver enzymes and bile flow.​

Uses & Indications

Doctors prescribe URNOZ 450 SR Tablet (UDCA 450 mg SR) for:

• Treatment of gallbladder stones composed mainly of cholesterol when surgery is not suitable or needs to be deferred.​

• Primary biliary cholangitis / primary biliary cirrhosis and other chronic cholestatic liver diseases.​

• Supportive treatment in alcoholic and non‑alcoholic fatty liver disease with cholestatic features, along with lifestyle modification.​

Therapy should always be supervised by a hepatologist or gastroenterologist.​

Dosage & Directions

Dose is based on body weight, indication and clinical response and must be set by the treating specialist.​

• Typical total dose for gallstone dissolution is about 8–10 mg/kg/day; a 450 mg SR tablet allows simplified once‑daily or divided dosing in appropriate patients.​

• Tablets are generally taken after meals with water or milk, with one of the doses preferably after the evening meal or at bedtime.​

Long‑term therapy requires regular monitoring of liver function and imaging to assess gallstones or disease progression.​

Price & Packaging

Ingram’s pricing section lists URNOZ 450 SR Tablet with an original price of ₹495 and a current price of ₹420.75 per strip. Retail platforms show similar MRPs with promotional discounts depending on the seller.​

The product is supplied as sustained‑release film‑coated tablets in Alu‑Alu blister strips (usually 10 tablets), packed in cartons bearing Ingram Biosciences branding and full composition and regulatory details.​

Side Effects & Safety

Side‑effect profile of URNOZ 450 SR is similar to other UDCA formulations. Common side effects include:​

• Abdominal pain, diarrhoea, abdominal discomfort, nausea, flatulence and vomiting.​

• Hair loss, itching, rash, headache, back pain, fatigue and dyspepsia; respiratory or urinary infections may also occur.​

Most effects are mild and transient; persistent diarrhoea or significant symptom worsening warrants medical review and possible dose change or discontinuation.​

Precautions & Contraindications

• Contraindicated in acute inflammation of gallbladder/bile ducts, complete biliary obstruction, non‑functional gallbladder, radiopaque/ calcified stones and certain advanced liver decompensations.​

• Use cautiously in patients with severe liver or renal impairment, portal hypertension complications (variceal bleeding, ascites, encephalopathy) and those on multiple hepatotoxic drugs.​

• Avoid aluminium‑containing antacids, cholestyramine and colestipol near dosing, as they reduce UDCA absorption; adequate spacing is required.​

Pregnancy and breastfeeding use should be based on careful risk–benefit assessment by the treating obstetrician and hepatologist.​

10 Frequently Asked Questions (FAQ)

1. What is URNOZ 450 SR Tablet used for?
It is used to dissolve selected cholesterol gallstones and to treat primary biliary cholangitis and other cholestatic liver diseases.​

2. How is URNOZ 450 SR different from URNOZ 300?
URNOZ 450 SR provides a higher, sustained‑release 450 mg dose, allowing more convenient dosing in patients needing higher daily UDCA.​

3. How long does it take to dissolve gallstones?
Gallstone dissolution may take several months to over a year and not all stones respond; regular ultrasound monitoring is required.​

4. Can weight gain occur with URNOZ 450 SR?
Weight gain is uncommon but reported in patients with chronic cholestatic liver disease; any unexpected weight change should be discussed with the doctor.​

5. When should I take URNOZ 450 SR?
It should be taken after meals with water or milk, with one dose ideally after the evening meal or at bedtime, as advised.​

6. Is long‑term use safe?
Long‑term UDCA is standard in conditions like PBC but needs periodic monitoring of liver enzymes, bilirubin and clinical status.​

7. Can I use antacids while on URNOZ 450 SR?
Antacids containing aluminium and bile acid–binding resins should be avoided close to dosing; ask your doctor about appropriate intervals.​

8. Does URNOZ 450 SR help in NAFLD?
UDCA may be used in NAFLD with cholestasis but is not a substitute for weight loss, diet and exercise, which remain central.​

9. What monitoring is needed?
Liver function tests and bilirubin are usually monitored monthly in the initial months, then periodically; imaging is done to track gallstones and liver status.​

10. Can URNOZ 450 SR be used in children?
UDCA is used in certain paediatric hepatobiliary diseases, but paediatric dosing and suitability must be decided by a paediatric hepatologist.​

Quick Tips

• Take URNOZ 450 SR Tablet exactly as prescribed; do not stop or change dose without medical advice.​

• Maintain a low‑fat diet, avoid alcohol and follow weight and exercise guidance to support liver and gallbladder health.​

• Seek immediate care if you develop severe abdominal pain, worsening jaundice, very dark urine or persistent diarrhoea.​

Why Choose Ingram BioSciences?

URNOZ 450 SR complements URNOZ 300, HEPAROL 400, SYLNOZ 400 and GRAMOZ‑BC within Ingram’s Gastro & Hepato Care basket, enabling stepwise and combination liver‑care strategies for clinics. Ingram operates from Jasola, New Delhi, presents clear physician‑only information and works as a specialised trader‑manufacturer in pharma tablets and capsules.​

This positioning makes URNOZ 450 SR a credible UDCA 450 mg SR option for Indian hepatologists and gastroenterologists.​

Customer Support & Ordering

For enquiries and ordering related to URNOZ 450 SR Tablet:

• Company: Ingram Biosciences Pvt Ltd.​

• Delhi Office: Office‑308, 3rd Floor, Living Style Mall, Jasola, New Delhi – 110025, India.​

• Phone / WhatsApp: +91 99997 81444; Mobile: +91 76690 11534.​

• Email: info@ingrambiosciences.in​

URNOZ 450 SR Tablet is available via hospitals, retail chemists, PCD/franchise partners and leading e‑pharmacies and should be used only on the prescription of a registered medical practitioner.